WO2006036007A3 - Modified-release preparation - Google Patents

Modified-release preparation Download PDF

Info

Publication number
WO2006036007A3
WO2006036007A3 PCT/JP2005/018486 JP2005018486W WO2006036007A3 WO 2006036007 A3 WO2006036007 A3 WO 2006036007A3 JP 2005018486 W JP2005018486 W JP 2005018486W WO 2006036007 A3 WO2006036007 A3 WO 2006036007A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
compound
ring
bond
group
Prior art date
Application number
PCT/JP2005/018486
Other languages
French (fr)
Other versions
WO2006036007A2 (en
Inventor
Akihiko Ono
Shuji Yoneyama
Original Assignee
Takeda Pharmaceutical
Akihiko Ono
Shuji Yoneyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical, Akihiko Ono, Shuji Yoneyama filed Critical Takeda Pharmaceutical
Publication of WO2006036007A2 publication Critical patent/WO2006036007A2/en
Publication of WO2006036007A3 publication Critical patent/WO2006036007A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

The present invention relates to a pharmaceutical agent comprising a combination of two or more parts comprising a compound of the formula:wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, or the like; m represents an integer of 0 to 3; Y represents an oxygen atom or the like; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X1 represents a bond or the like; R2 represents a hydrogen atom or the like; W represents a bond or the like; R3 represents a group of the formula: -OR8 (R8 represents a hydrogen atom or a hydrocarbon group which may be substituted) or the like; or a salt thereof, said two or more parts have mutually different release rates of the compound or a salt thereof. According to the present invention, a pharmaceutical agent comprising a nitrogen containing 5-membered heterocyclic compound useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, arteriosclerosis and the like, which has improved sustainability of an effective blood concentration of the compound, can be provided.
PCT/JP2005/018486 2004-09-30 2005-09-29 Modified-release preparation WO2006036007A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004287244 2004-09-30
JP2004-287244 2004-09-30

Publications (2)

Publication Number Publication Date
WO2006036007A2 WO2006036007A2 (en) 2006-04-06
WO2006036007A3 true WO2006036007A3 (en) 2006-09-14

Family

ID=36119292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/018486 WO2006036007A2 (en) 2004-09-30 2005-09-29 Modified-release preparation

Country Status (2)

Country Link
TW (1) TW200616679A (en)
WO (1) WO2006036007A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081891A1 (en) * 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
WO2011049309A2 (en) 2009-10-09 2011-04-28 영진약품공업 주식회사 Pharmaceutical composition with both immediate and extended release characteristics
WO2011055385A1 (en) * 2009-11-03 2011-05-12 Lupin Limited Modified release formulation of lacosamide
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457490A1 (en) * 1999-11-10 2004-09-15 Takeda Chemical Industries, Ltd. 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
EP1541564A1 (en) * 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457490A1 (en) * 1999-11-10 2004-09-15 Takeda Chemical Industries, Ltd. 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
EP1541564A1 (en) * 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds

Also Published As

Publication number Publication date
WO2006036007A2 (en) 2006-04-06
TW200616679A (en) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2005097129A3 (en) 6-azaindole compound
EP1679309A4 (en) Antistress drug and medical use thereof
WO2008114817A1 (en) Novel adenine compound
WO2009016841A1 (en) Oxopyrazine derivative and herbicide
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
EP1775289A4 (en) Novel imidazolidine derivatives
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
TW200637869A (en) The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
TW200505919A (en) DPP-IV inhibitors
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
TW200745034A (en) New compounds
WO2008108380A3 (en) Pyrrole compounds
WO2009057784A1 (en) Heterocyclic compound
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
GEP20125637B (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
MX2010001566A (en) Aminopyrazole amide derivative.
WO2006036007A3 (en) Modified-release preparation
WO2006002802A8 (en) Phenyl derivatives comprising an acetylene group
WO2008049997A8 (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
NO20070617L (en) Quinolone-containing medicinal mixtures.
MX2007003911A (en) Benzoxazine and quinoxaline derivatives and uses.
WO2007027719A3 (en) Lisofylline analogues and their pharmeacuetical uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 05790424

Country of ref document: EP

Kind code of ref document: A2